GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice
Background: The interpretation of antibodies to glutamic acid decarboxylase 65 (GAD-Abs) in neurological practice is challenging. GAD-Abs are not considered directly pathogenic and immunotherapy guidelines are lacking. Methods: We undertook a single-center retrospective service evaluation of GAD-Abs...
Asıl Yazarlar: | Brown, RL, Thomas-Black, G, Garcia-Moreno, H, Chou, M, Fleszar, Z, Zandi, MS, Chapman, M, Church, AJ, Hart, M, Giunti, P, Vincent, A, Lunn, MP |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Springer
2025
|
Benzer Materyaller
-
Characterisation of anti-GAD antibodies in stiff-person syndrome
Yazar:: Chang, T, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
Stiff, twitchy or wobbly - Are GAD antibodies pathogenic?
Yazar:: Vincent, A
Baskı/Yayın Bilgisi: (2008) -
Stiff, twitchy or wobbly: are GAD antibodies pathogenic?
Yazar:: Vincent, A
Baskı/Yayın Bilgisi: (2008) -
GAD antibodies in stiff-person syndrome.
Yazar:: Chang, T, ve diğerleri
Baskı/Yayın Bilgisi: (2004) -
GAD65 Antibody-Associated Epilepsy
Yazar:: Justina Valinčiūtė, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)